Market Definition:
The Global Glaucoma Surgery Devices Market size was valued at USD 786.5 million in 2019 is predicted to garner USD 7.97 billion by 2030, with a CAGR of 23.6% from 2020-2030.
Glaucoma is an ocular disease that affects the optic nerve of the iris diaphragm, and progression of the same results in optic nerve damage or vision loss. In glaucoma, intraocular pressure build-up within the eye due to excessive accumulation of eye-fluid; this may lead to eye-sight damage or blindness. According to the World Health Organization (WHO), glaucoma is the major cause of blindness, specifically in people aged over 60 years, across the globe.
Glaucoma surgery devices play a vital role while operating the patients suffering from glaucoma, hence are adopted on a large scale world-wide. These include various Lasik and non-Lasik implants as well as other such devices that help in reducing the intraocular pressure, thereby leveraging the ocular pressure. In the treatment of glaucoma, optical surgeons either use conventional glaucoma surgeries or minimal invasive glaucoma surgeries.
Market Dynamics and Trends
About 2.7 million Americans ageing 40 years or above suffer from open-angle glaucoma disorder, 3.3 million are affected by blindness or low-vision, and more than 3 million Americans are living with glaucoma disease. The increasing prevalence of glaucoma at global level, as well as constantly multiplying number of geriatric populations world-wide are the key factors driving the growth of global glaucoma surgery devices market.
Furthermore, higher inclination towards minimal invasive surgeries, increasing consumer awareness regarding treatment of this disease, advancements in healthcare infrastructures, and innovative developments in the product technologies, are the factors anticipated in propelling the growth of the global glaucoma surgery devices market throughout the forecast period.
However, less awareness regarding glaucoma treatment in the underdeveloped countries, shortage of skilled medical professionals, and risk of post-operative complications associated with glaucoma surgeries are hampering the growth of the glaucoma surgery devices market.
On contrary, factors such as, higher investments in R&D activities, increase in number of campaigns by government & non-government organization for spreading awareness regarding glaucoma treatment, and untapped market opportunities in the emerging economies, shall pave the way for lucrative opportunities in the global glaucoma surgery devices market in coming future.
Market Segmentations and Scope of the Study:
The glaucoma surgery devices market share has been analyzed based on surgery type, product, end user, and geography.
Based on surgery type, the market is segmented into conventional glaucoma surgeries and minimally invasive glaucoma surgeries. The product segment is further divided into glaucoma drainage devices, glaucoma laser devices, and implants & stents. Based on the end user, the market covers eye hospitals, ophthalmology clinics, and outpatient surgical centers. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
Geographical Analysis
North America is anticipated to hold the highest glaucoma surgery devices market share throughout the forecast period owing to higher prevalence of glaucoma in this region, increasing adoption of technologically advanced devices for glaucoma surgeries, and better reimbursement facilities.
Asia-Pacific region shall witness an increasing glaucoma surgery devices market size owing to improvement in the healthcare facility and growing awareness about treatment options.
Competitive Landscape
Comprehensive competitive analysis and profiles of the major market players such as Ellex Medical Lasers Ltd., Abbott Laboratories, Johnson & Johnson, Alcon, Inc., Topcon Corporation, Glaukos Corporation, New World Medical, Inc., Bausch & Lomb, Inc., Lumenis Ltd., Allergan Plc, and others are provided in the glaucoma surgery devices market report.
An upsurge in R&D activities and advancement in product technologies along with new product launches by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global glaucoma surgery devices market.
For instance, in November 2019, Glaukos Corporation completed its acquisition over Avedro, Inc, resulting into the amalgamation of two highly complementary hybrid pharma & devices organizations. Where Galukos is a pioneer ophthalmic medical-technology & pharmaceutical company in the global glaucoma surgery devices market engrossed in the innovation of novel therapies for treatment of corneal disorders, glaucoma, and retinal diseases; Avedro is a chief commercial-stage ophthalmic medical-technology company engrossed in treating corneal ectatic disorders as well as in improving vision. This acquisition shall reinforce Glaukos’s global commercial sale, market-building, extensive clinical & regulatory infrastructure, and reimbursement expertise, with Averdo’s novel bio-activated pharmaceutical solutions and R&D activities.
Furthermore, in March 2020, Allergan Plc., now acquired by AbbVie Inc., announced that it has received FDA approval for its ‘DURYSTA,’ the bimatoprost implant (10 mcg) for intracameral administration. With this DURYSTA becomes the first-ever ‘intracameral, biodegradable sustained-release implant designated to lower the intraocular pressure in patients suffering from ocular hypertension or open-angle glaucoma. DURYSTA is capable of reducing the intraocular pressure by approximately 30%. Allergan is a leading pharmaceutical company ruling the global glaucoma surgery devices market from more than 70 years. With this milestone Allergen makes a hefty contribution for the glaucoma community, as well as provides a much-needed alternative for patients suffering from topical drops, OAG, OHT, or vision problems.
Key Market Segments:
Global Glaucoma Surgery Devices Market - By Surgery Type
The Global Glaucoma Surgery Devices Market size was valued at USD 786.5 million in 2019 is predicted to garner USD 7.97 billion by 2030, with a CAGR of 23.6% from 2020-2030.
Glaucoma is an ocular disease that affects the optic nerve of the iris diaphragm, and progression of the same results in optic nerve damage or vision loss. In glaucoma, intraocular pressure build-up within the eye due to excessive accumulation of eye-fluid; this may lead to eye-sight damage or blindness. According to the World Health Organization (WHO), glaucoma is the major cause of blindness, specifically in people aged over 60 years, across the globe.
Glaucoma surgery devices play a vital role while operating the patients suffering from glaucoma, hence are adopted on a large scale world-wide. These include various Lasik and non-Lasik implants as well as other such devices that help in reducing the intraocular pressure, thereby leveraging the ocular pressure. In the treatment of glaucoma, optical surgeons either use conventional glaucoma surgeries or minimal invasive glaucoma surgeries.
Market Dynamics and Trends
About 2.7 million Americans ageing 40 years or above suffer from open-angle glaucoma disorder, 3.3 million are affected by blindness or low-vision, and more than 3 million Americans are living with glaucoma disease. The increasing prevalence of glaucoma at global level, as well as constantly multiplying number of geriatric populations world-wide are the key factors driving the growth of global glaucoma surgery devices market.
Furthermore, higher inclination towards minimal invasive surgeries, increasing consumer awareness regarding treatment of this disease, advancements in healthcare infrastructures, and innovative developments in the product technologies, are the factors anticipated in propelling the growth of the global glaucoma surgery devices market throughout the forecast period.
However, less awareness regarding glaucoma treatment in the underdeveloped countries, shortage of skilled medical professionals, and risk of post-operative complications associated with glaucoma surgeries are hampering the growth of the glaucoma surgery devices market.
On contrary, factors such as, higher investments in R&D activities, increase in number of campaigns by government & non-government organization for spreading awareness regarding glaucoma treatment, and untapped market opportunities in the emerging economies, shall pave the way for lucrative opportunities in the global glaucoma surgery devices market in coming future.
Market Segmentations and Scope of the Study:
The glaucoma surgery devices market share has been analyzed based on surgery type, product, end user, and geography.
Based on surgery type, the market is segmented into conventional glaucoma surgeries and minimally invasive glaucoma surgeries. The product segment is further divided into glaucoma drainage devices, glaucoma laser devices, and implants & stents. Based on the end user, the market covers eye hospitals, ophthalmology clinics, and outpatient surgical centers. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
Geographical Analysis
North America is anticipated to hold the highest glaucoma surgery devices market share throughout the forecast period owing to higher prevalence of glaucoma in this region, increasing adoption of technologically advanced devices for glaucoma surgeries, and better reimbursement facilities.
Asia-Pacific region shall witness an increasing glaucoma surgery devices market size owing to improvement in the healthcare facility and growing awareness about treatment options.
Competitive Landscape
Comprehensive competitive analysis and profiles of the major market players such as Ellex Medical Lasers Ltd., Abbott Laboratories, Johnson & Johnson, Alcon, Inc., Topcon Corporation, Glaukos Corporation, New World Medical, Inc., Bausch & Lomb, Inc., Lumenis Ltd., Allergan Plc, and others are provided in the glaucoma surgery devices market report.
An upsurge in R&D activities and advancement in product technologies along with new product launches by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global glaucoma surgery devices market.
For instance, in November 2019, Glaukos Corporation completed its acquisition over Avedro, Inc, resulting into the amalgamation of two highly complementary hybrid pharma & devices organizations. Where Galukos is a pioneer ophthalmic medical-technology & pharmaceutical company in the global glaucoma surgery devices market engrossed in the innovation of novel therapies for treatment of corneal disorders, glaucoma, and retinal diseases; Avedro is a chief commercial-stage ophthalmic medical-technology company engrossed in treating corneal ectatic disorders as well as in improving vision. This acquisition shall reinforce Glaukos’s global commercial sale, market-building, extensive clinical & regulatory infrastructure, and reimbursement expertise, with Averdo’s novel bio-activated pharmaceutical solutions and R&D activities.
Furthermore, in March 2020, Allergan Plc., now acquired by AbbVie Inc., announced that it has received FDA approval for its ‘DURYSTA,’ the bimatoprost implant (10 mcg) for intracameral administration. With this DURYSTA becomes the first-ever ‘intracameral, biodegradable sustained-release implant designated to lower the intraocular pressure in patients suffering from ocular hypertension or open-angle glaucoma. DURYSTA is capable of reducing the intraocular pressure by approximately 30%. Allergan is a leading pharmaceutical company ruling the global glaucoma surgery devices market from more than 70 years. With this milestone Allergen makes a hefty contribution for the glaucoma community, as well as provides a much-needed alternative for patients suffering from topical drops, OAG, OHT, or vision problems.
Key Market Segments:
Global Glaucoma Surgery Devices Market - By Surgery Type
- Conventional Glaucoma Surgeries
- Minimally Invasive Glaucoma Surgeries
- Glaucoma Drainage Devices
- Glaucoma Laser Devices
- Implants & Stents
- Eye Hospitals
- Ophthalmology Clinics
- Outpatient Surgical Centers
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Rest of World
- Turkey
- Saudi Arabia
- South Africa
- Brazil
- Remaining countries
Table of Contents
1. Introduction
2. Market Snapshot, 2019-2030 Million Usd
4. Market Dynamics
5. Global Glaucoma Surgery Devices Market, by Surgery Type
6. Global Glaucoma Surgery Devices Market, by Product
7. Global Glaucoma Surgery Devices Market, by End-user
8. Global Glaucoma Surgery Devices Market, by Region
9. Company Profiles
Executive Summary
Glaucoma Surgery: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2020 - 2030Increasing consumer awareness regarding treatment of this disease, advancements in healthcare infrastructures are key driving factors accountable for glaucoma surgery market growth.
Glaucoma is an ocular disease that affects the optic nerve of the iris diaphragm, and progression of the same results in optic nerve damage or vision loss. In glaucoma, intraocular pressure build-up within the eye due to excessive accumulation of eye-fluid; this may lead to eye-sight damage or blindness. According to the World Health Organization (WHO), glaucoma is the major cause of blindness, specifically in people aged over 60 years, across the globe.
Glaucoma surgery devices play a vital role while operating the patients suffering from glaucoma, hence are adopted on a large scale world-wide. These include various Lasik and non-Lasik implants as well as other such devices that help in reducing the intraocular pressure, thereby leveraging the ocular pressure. The increasing prevalence of glaucoma at global level, as well as constantly multiplying number of geriatric populations world-wide are the key factors driving the growth of global glaucoma surgery devices market.
The glaucoma surgery devices market share has been segmented on the basis of surgery type, product, end user, and geography. Based on surgery type, the market is segmented into conventional glaucoma surgeries and minimally invasive glaucoma surgeries. The product segment is further divided into glaucoma drainage devices, glaucoma laser devices, and implants & stents. Based on the end user, the market covers eye hospitals, ophthalmology clinics, and outpatient surgical centers. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Alcon, Inc
- Glaukos Corporation
- New World Medical, Inc
- Ellex Medical Lasers Ltd
- Abbott Medical Optics
- Johnson & Johnson
- Bausch & Lomb, Inc
- Topcon Corporation
- Lumenis Ltd.
- Allergan plc
